Geode Capital Management
OTLK icon

Geode Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Geode Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$124K Buy
603,606
+287,142
+91% +$124K ﹤0.01% 4076
2025
Q4 		$500K Buy
316,464
+10,169
+3% +$16.2K ﹤0.01% 3586
2025
Q3 		$325K Buy
306,295
+40,664
+15% +$70.3K ﹤0.01% 3764
2025
Q2 		$425K Sell
265,631
-168,222
-39% -$268K ﹤0.01% 3605
2025
Q1 		$529K Buy
433,853
+86,624
+25% +$152K ﹤0.01% 3518
2024
Q4 		$656K Buy
347,229
+5,270
+2% +$21.7K ﹤0.01% 3519
2024
Q3 		$1.83M Buy
341,959
+112,812
+49% +$826K ﹤0.01% 3156
2024
Q2 		$1.69M Buy
229,147
+77,567
+51% +$623K ﹤0.01% 3161
2024
Q1 		$1.81M Buy
151,580
+3,063
+2% +$24.8K ﹤0.01% 3147
2023
Q4 		$1.17M Buy
148,517
+9,343
+7% +$79K ﹤0.01% 3295
2023
Q3 		$615K Buy
139,174
+3,134
+2% +$69.3K ﹤0.01% 3527
2023
Q2 		$4.73M Buy
136,040
+9,156
+7% +$250K ﹤0.01% 2714
2023
Q1 		$2.77M Buy
126,884
+23,774
+23% +$532K ﹤0.01% 2898
2022
Q4 		$2.23M Sell
103,110
-75
-0.1% -$1.63K ﹤0.01% 2995
2022
Q3 		$2.52M Buy
103,185
+295
+0.3% +$6.86K ﹤0.01% 3005
2022
Q2 		$2.1M Buy
102,890
+9,660
+10% +$278K ﹤0.01% 3096
2022
Q1 		$3.32M Buy
93,230
+16,539
+22% +$516K ﹤0.01% 3012
2021
Q4 		$2.09M Sell
76,691
-931
-1% -$33.2K ﹤0.01% 3343
2021
Q3 		$3.37M Buy
77,622
+1,818
+2% +$87.7K ﹤0.01% 3138
2021
Q2 		$3.77M Buy
75,804
+38,720
+104% +$1.8M ﹤0.01% 3062
2021
Q1 		$1.67M Buy
37,084
+23,652
+176% +$906K ﹤0.01% 3343
2020
Q4 		$349K Buy
13,432
+3,128
+30% +$65.4K ﹤0.01% 3712
2020
Q3 		$148K Buy
10,304
+4,329
+72% +$96.5K ﹤0.01% 3808
2020
Q2 		$154K Buy
5,975
+2,613
+78% +$46.6K ﹤0.01% 3737
2020
Q1 		$40K Hold
3,362
– – ﹤0.01% 3959
2019
Q4 		$39K Hold
3,362
– – ﹤0.01% 4112
2019
Q3 		$100K Buy
3,362
+1,738
+107% +$67K ﹤0.01% 3947
2019
Q2 		$67K Buy
+1,624
New +$75.7K ﹤0.01% 4034
2019
Q1 		– Sell
-70
Closed -$5K – 4145
2018
Q4 		$5K Hold
70
– – ﹤0.01% 4137
2018
Q3 		$10K Hold
70
– – ﹤0.01% 4112
2018
Q2 		$9K Hold
70
– – ﹤0.01% 4057
2018
Q1 		$9K Hold
70
– – ﹤0.01% 4036
2017
Q4 		$14K Hold
70
– – ﹤0.01% 4003
2017
Q3 		$15K Hold
70
– – ﹤0.01% 4025
2017
Q2 		$11K Sell
70
-24
-26% -$6.78K ﹤0.01% 4073
2017
Q1 		$40K Buy
+94
New +$46.7K ﹤0.01% 3981

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Geode Capital Management's OTLK Position: Q1 2026 in Review

Geode Capital Management increased its Outlook Therapeutics (OTLK) stake by 91% in Q1 2026, buying an estimated $124K and bringing the position to 603,606 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #4076.

Geode Capital Management first reported a position in OTLK in Q1 2017 and has held it in 36 quarters since. The position peaked at $4.73M in Q2 2023. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Geode Capital Management held 603,606 shares of Outlook Therapeutics worth $124K as of Q1 2026.
  • Geode Capital Management bought 287,142 Outlook Therapeutics shares in Q1 2026, an estimated $124K.
  • Outlook Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4076 holding.
  • Geode Capital Management first reported a position in Outlook Therapeutics in Q1 2017 and has held it in 36 quarters since.
  • Geode Capital Management's Outlook Therapeutics position peaked at $4.73M in Q2 2023.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.